Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13 Esophageal Neoplasms 4 Stomach Neoplasms 3 Colorectal Neoplasms 3 Adenocarcinoma Of Esophagus 3 Prostatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 HER2-positive Breast Cancer 2 Endometrial Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Solid Tumors 1 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Melanoma 1 Malignant Solid Neoplasm 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1

Interventions

Cisplatin 5 Gemcitabine 4 Oxaliplatin 2 Irinotecan 2 Fluorouracil 2 Capecitabine 2 Bevacizumab 2 zanidatamab 1 toripalimab 1 pembrolizumab 1 niraparib 1 neratinib 1 ivosidenib 1 futibatinib 1 fludarabine 1 envafolimab 1 encorafenib 1 durvalumab 1 binimetinib 1 Trastuzumab 1 Pemetrexed 1 Nivolumab 1 Folfox protocol 1 Docetaxel 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Actigraphy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × Trastuzumab × 30 days × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡